U.S. COMPANY FILING
ALNYLAM PHARMACEUTICALS, INC. — Form 10-Q filed 2025-10-30
Filing text preview
Alnylam reported Q3 2025 revenues of $1.25B, up 149% YoY, with net income of $251M vs. a loss of $112M in Q3 2024. AMVUTTRA and ONPATTRO generated $685M and $39M in global net product revenues, respectively. The company issued $661.25M of 0% convertible notes due 2028 and advanced late-stage pipeline including zilebesiran and cemdisiran.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record